• A total of 660 patients were enrolled at 34 sites in the United States and Europe. 214 patients were obese, 29% (193/214) of the obese patients had HRQL data for inclusion in this analysis.
Baseline Characteristics in Cured versus Improved Patients (Table 1) • In order to understand the factors that may contribute to obese patients who did not proceed to cure, an analysis was conducted on the baseline characteristics of patients who were in the cured and improved groups at LFU.
• Obese patients who remained improved at LFU (who did not progress to cure by LFU) were more likely to have diabetes, an infection on the lower extremities, a MRSA infection, and required an additional 1.4 days of treatment. Upper extremities 34 (24.3) 7 (22.6) *Includes American Indian, Alaska Native, Asian, American Native Hawaiian, and Other Pacific Islander **surgical debridement occurred prior to initiating study treatment
Investigator Assessed Response of Obese Patients at Each Time Point (Figure 1)
• At EOT, the investigators assessed that 55% (118/214) of the patients were improved and 26% (170/660) were fully cured.
• At FU, 31% (66/214) of the patients were improved and 51% (110/214) of the patients progressed to cure.
• At LFU, 14% (31/214) of the patients remained improved and had not proceeded to cure. 65% (140/214) of the patients were cured.
• The physician's assumption is that all patients would move to cure after the EOT. However, in the average 15.74 days from EOT to LFU, 31 patients were still improved at LFU, compared to the 118 improved at EOT. Approximately 26% of the patients who had been improved at EOT still had not progressed to cure by LFU. • Cured obese patients had a statistically significant greater mean percent change in lesion size than improved patients at each assessment. ▪ At EOT, the mean percent change in lesion size from baseline was 82.0% for improved patients and 96.7% for cured patients. ▪ At LFU, the mean percent change in lesion size from baseline was 79.7% for improved patients and 99.6% for patients who were cured. • Improved patients had a significantly higher pain score at each assessment than cured patients. ▪ At EOT, improved patients had a mean pain score of 3.2 compared to 0.4 in cured patients. ▪ At LFU, improved patients' pain persisted, with a mean pain score of 2 compared to 0.6 in cured patients. • Improved obese patients had a higher mean number of signs and symptoms than cured obese patients at each assessment. ▪ At EOT, improved patients had an average of 2.8 signs and symptoms, compared to improved patients who had 0.8. ▪ At LFU, improved obese patients had a mean 1.8 remaining signs and symptoms compared to cured obese patients who had complete resolution of signs and symptoms. , a 20-question survey using a 5-point Likert scale (5 equals highest degree of importance/impairment to the patients), measured symptoms, daily functioning, emotional functioning, and social interactions.
RESULTS
Obese patients comprised 29% of the study (660 patients, 589 included in analysis, 193 obese). IOP at EOT were less likely to proceed to cure than non-obese patients (26%, 16%) at LFU. The ESTI Score was higher at LFU in IOP than COP (46.4, 26.3, p=0.029) . At LFU, IOP were more likely than COP to report having continued difficulty performing a job (29.0%, 9.6%, p=0.008) and earning an income (32.3%, 14.0%, p=0.032). , are among the most common infections for obese patients. 4 • Obesity is a significant risk factor for antibiotic treatment failure.
CONCLUSIONS
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• Obese patients with cellulitis have been shown to have high readmission rates. In a retrospective cohort study, 38.6% patients who were obese and admitted for cellulitis were classified as "30-day bounce backs," including readmissions (12.4%), visits to the ER (10.9%), outpatient clinic (11.4%) or urgent care center (2.9%), and self-care (1.0%).
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• When treating ABSSSIs, a HCP's decision to stop antibiotics is empirical. ▪ Typically the HCP stops antibiotics when they feel that the patient is cured (no remaining signs or symptoms) or significantly improved, where some but not all signs and symptoms have resolved. In this case, the HCP assumes that all remaining signs and symptoms will resolve over time so that the patient is fully cured without further antibiotics. ▪ Limited data exists on the outcome of patients who are cured versus improved after antibiotic discontinuation.
• An analysis was conducted to assess the difference between cured and improved obese patients with respect to lesion size, signs and symptoms, pain score, and patient reported HRQL, to understand what patients "look like" when their antibiotics are discontinued (i.e. what separates a cured from an improved patient), and to understand if the physician's assumption of their patients' progression from "improved" to "cure" over time is correct. ■
Introduction
Methods
Study Design
• Adult patients with a diagnosis of ABSSSI were enrolled in a prospective phase 3, randomized, double-blind study to evaluate antibiotic treatment in patients with ABSSSI.
• At baseline, patients were required to have a minimum ABSS-SI lesion size of 75 cm 2 and at least two systemic manifestations of infection.
• The antibiotic therapy was required for a minimum of five days, extending up to 14 days at the discretion of the investigator.
• Signs and symptoms were assessed at each visit. The eight signs/symptoms included: drainage/discharge, erythema/extension of redness, fluctuance, heat/ localized warmth, swelling/induration, pain/tenderness, lymphangitis, lymphadenopathy.
• The lesion size was assessed at each visit by digital planimetry.
• Patients assessed pain via a numerical rating scale (0=no pain, 10=worst pain; typically a change in pain score of approximately 1.3 is the minimally clinically important difference).
• The Investigator was asked for their clinical assessment of the patient's outcome as defined as:
▪ Cured: The complete resolution of all baseline signs and symptoms of ABSSSI.
▪ Improved: Some symptoms remained, but the patient was improved to an extent that no additional antibiotic treatment was necessary.
▪ Failure: worsening of signs and symptoms that require unplanned surgical intervention or nonstudy antibacterial drug therapy was required because of lack of efficacy.
▪ Indeterminate: A response could not be assigned because an assessment was not completed at the FU or LFU or because the patient received potentially effective nonstudy antibacterial drug therapy for treatment of a condition other than ABSSSI unless that patient was a failure.
Health Related Quality of Life (HRQL) Measurement:
• An HRQL assessment was completed in all patients as measured by a questionnaire utilizing the Extremity Soft Tissue Infections (ESTI) score.
▪ The ESTI-Score is a novel instrument designed to quantify the impact of extremity soft tissue infections on the following quality of life parameters: ▪ Patients were asked to respond yes/no to whether they were experiencing difficulty with each item and rank the "importance" using a 5-point Likert. A higher ESTI-Score represents that a patient reported more difficulties with the HRQL measure.
This full menu of assessments was performed at the End of Treatment (EOT) and was repeated at follow up (FU, study day 14±1) and late follow up (LFU, study day 21-28). ■
Results
In this study, at the point when physicians decide to stop antibiotic treatment (EOT), the majority obese patients have residual signs and symptoms, with the presumption that complete cure will occur without further antibiotics. While most improved patients did proceed to cure by LFU, approximately 26% of those patients who were improved at EOT did not progress to full cure and continued to have problems related to their infection, including:
• Remaining lesion
• Persistent signs and symptoms • Higher pain score • Greater difficulties with HRQL measures, including doing a job and earning an income
Obese patients who did not proceed to cure at LFU were more likely to have diabetes, an infection on the lower extremities, a MRSA infection, and require 1.4 more days of treatment. These patients may require further utilization of health care resources and potentially lower patient satisfaction ratings. Additional research is needed to determine the potential economic impact of these data. ■ HRQL (Table 2) • Across all ESTI parameters, improved obese patients reported greater difficulty with HRQL measures.
Conclusions
• The total ESTI-Score was higher at LFU in improved obese patients than cured 46.2, 26.2, p=0.0289).
• At LFU improved obese patients were more likely than cured obese patients to report having continued difficulty performing a job (29%, 10%, p=0.0075) and earning an income (32%, 14%, p=0.0320). 
